These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854 [TBL] [Abstract][Full Text] [Related]
3. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799 [TBL] [Abstract][Full Text] [Related]
4. Prediction of coexisting invasive carcinoma on ductal carcinoma in situ (DCIS) lesions by mass spectrometry imaging. Chen H; Li X; Li F; Li Y; Chen F; Zhang L; Ye F; Gong M; Bu H J Pathol; 2023 Oct; 261(2):125-138. PubMed ID: 37555360 [TBL] [Abstract][Full Text] [Related]
5. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics. Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454 [TBL] [Abstract][Full Text] [Related]
6. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106 [TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755 [TBL] [Abstract][Full Text] [Related]
8. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365 [TBL] [Abstract][Full Text] [Related]
9. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365 [TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Allred DC; Wu Y; Mao S; Nagtegaal ID; Lee S; Perou CM; Mohsin SK; O'Connell P; Tsimelzon A; Medina D Clin Cancer Res; 2008 Jan; 14(2):370-8. PubMed ID: 18223211 [TBL] [Abstract][Full Text] [Related]
11. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact. Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021 [TBL] [Abstract][Full Text] [Related]
12. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467 [TBL] [Abstract][Full Text] [Related]